Comparative Efficacy of Three Preparations of Botox-A in Treating Spasticity
Stroke, Brain Injuries, Spasticity
About this trial
This is an interventional treatment trial for Stroke focused on measuring Stroke, Brain Injuries, Spasticity, Botulinum Toxins
Eligibility Criteria
Inclusion Criteria - Spasticity resulting from ABI (stroke, including vascular malformations, traumatic brain injury) Ashworth Score (resting) of at least 2 of the primary ankle plantarflexor (gastrocnemius) Onset of primary illness at least six months prior to study inclusion At least 12 years of age Exclusion Criteria - Hypersensitivity or allergy to botulinum toxin History of myasthenia gravis or other neuromuscular disease Current use of aminoglycosides Botulinum toxin or phenol injection to study limb within six months prior to recruitment Current use of other spasmolytic drug, such as diazepam, baclofen, dantrolene, tizanidine Presence of contracture or significant muscle atrophy Pregnancy
Sites / Locations
- Kessler Institute for Rehabiliation
- Memorial Hermann Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Active Comparator
Other
1 - Low Volume, High Dose
2 - High Volume, High Dose
3 - High Volume, Low Dose
Botox (onabotulinumtoxinA), 150 units prepared as 100 units per 1 ml of preservative-free normal saline
Botox (onabotulinumtoxinA), 150 units prepared as 50 units per 1 ml of preservative-free normal saline
Botox (onabotulinumtoxinA), 75 units prepared as 25 units per 1 ml of preservative-free normal saline